Medication therapy of biological agents in osteoporosis: an evidence-based practice guideline (2025)_Chinese Journal of Evidence-Based Medicine

Authors：

 Chinese Pharmaceutical Association Evidence-Based Pharmacy Committee , Chinese Hospital Association Pharmaceutical Specialized Committee , Beijing Research Association for Chronic Diseases Control and Health Education of Osteoporosis Specialized Committee

Corresponding?author：

Chinese Pharmaceutical Association Evidence-Based Pharmacy Committee, Email: zhaorongsheng@bjmu.edu.cn

Keywords：

Osteoporosis; Biologics; Denosumab; Teriparatide; Guideline

DOI：

10.7507/1672-2531.202512048

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective With the increasing clinical application of biologics in osteoporosis treatment, challenges such as insufficient evidence for rational drug use and a lack of evidence-based guidance have emerged in clinical practice. To address these issues, the Committee of Evidence-Based Pharmacy of Chinese Pharmaceutical Association, the Pharmaceutical Specialized Committee of Chinese Hospital Association and the Committee of Osteoporosis of Beijing Research Association for Chronic Diseases Control and Health Education jointly developed the medication therapy of biological agents in osteoporosis: an evidence-based practice guideline (2025). It aims to standardize the medication therapy of osteoporosis biologics (Denosumab and Teriparatide). Methods The design, planning, development process, and reporting of this guideline adhered to international methodological standards, such as the WHO handbook for guideline development. We integrated the three core principles of evidence-based medicine: systematic evidence analysis using evidence-based pharmacy methods, evidence quality assessment via the GRADE framework, incorporation of patient preferences through surveys, and consolidation of multidisciplinary expert clinical experience via the Delphi method. This guideline was registered on the International Practice Guidelines Registry Platform (Registration No. IPGRP-2022CN386), with development initiated in July 2022 and finalized in October 2025. Results This guideline established a decision-making framework comprising 28 recommendations, covering the entire pharmaceutical care process for Denosumab and Teriparatide in osteoporosis treatment: pre-treatment assessment (9 recommendations), formulation of treatment protocol (11 recommendations), monitoring and management during treatment (6 recommendations), and sequential therapy after discontinuation (2 recommendations). Conclusion As the first clinical practice guideline for osteoporosis biologics developed based on the integration of evidence, experts’ clinical experience, and patient preferences, it proposes an innovative pharmaceutical care strategy (assessment-treatment-monitoring-sequential therapy). Multidisciplinary clinical teams may refer to this guideline to deliver pharmaceutical services and patient management throughout the pre-treatment, during-treatment, and post-treatment phases of Denosumab and Teriparatide therapy for osteoporosis patients.

Citation： Chinese Pharmaceutical Association Evidence-Based Pharmacy Committee, Chinese Hospital Association Pharmaceutical Specialized Committee, Beijing Research Association for Chronic Diseases Control and Health Education of Osteoporosis Specialized Committee. Medication therapy of biological agents in osteoporosis: an evidence-based practice guideline (2025). Chinese Journal of Evidence-Based Medicine, 2026, 26(7): 745-765. doi: 10.7507/1672-2531.202512048 Copy

1.	鈣劑預防成人原發性骨質疏松癥臨床實踐指南工作組. 鈣劑預防成人原發性骨質疏松癥的臨床實踐指南. 中國循證醫學雜志, 2024, 24(10): 1117-1128.
2.	中國疾病預防控制中心慢性非傳染性疾病預防控制中心, 中華醫學會骨質疏松和骨礦鹽疾病分會. 中國骨質疏松癥流行病學調查報告(2018). 北京: 人民衛生出版社, 2021.
3.	中華醫學會骨質疏松和骨礦鹽疾病分會. 原發性骨質疏松癥診療指南(2022). 中國全科醫學, 2023, 26(14): 1671-1691.
4.	中國醫師協會風濕免疫科醫師分會, 中華醫學會風濕病學分會, 中華醫學會骨質疏松和骨礦鹽疾病分會, 等. 2020版中國糖皮質激素性骨質疏松癥防治專家共識. 中華內科雜志, 2021, 60(1): 13-21.
5.	中國老年學和老年醫學學會骨質疏松分會婦產科專家委員會與圍絕經期骨質疏松防控培訓部. 圍絕經期和絕經后婦女骨質疏松防治專家共識. 中國臨床醫生雜志, 2020, 48(8): 903-908.
6.	《中國老年骨質疏松癥診療指南2023》工作組, 中國老年學和老年醫學學會骨質疏松分會, 中國醫療保健國際交流促進會骨質疏松病學分會, 等. 中國老年骨質疏松癥診療指南(2023). 中華骨與關節外科雜志, 2023, 16(10): 865-885.
7.	中華醫學會骨質疏松和骨礦鹽疾病分會. 男性骨質疏松癥診療指南. 中華骨質疏松和骨礦鹽疾病雜志, 2020, 13(5): 381-395.
8.	中華醫學會骨質疏松和骨礦鹽疾病分會. 地舒單抗在骨質疏松癥臨床合理用藥的中國專家建議. 中華骨質疏松和骨礦鹽疾病雜志, 2020, 13(6): 499-508.
9.	中國康復技術轉化與發展促進會骨質疏松性骨折加速康復專業委員會, 中華醫學會骨質疏松和骨礦鹽疾病委員會骨與關節學組, 中國醫師協會骨科醫師分會骨質疏松工作委員會. 特立帕肽治療骨質疏松性骨折中國專家共識(2024版). 中華醫學雜志, 2024, 104(17): 1456-1465.
10.	World Health Organization. WHO handbook for guideline development (2nd edition). 2014.
11.	Schünemann F, Meerpohl JJ, Schwingshackl L, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Z Evid Fortbild Qual Gesundhwes, 2021, 163: 76-84.
12.	Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol, 2010, 63(12): 1308-1311.
13.	Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
14.	楊楠, 趙巍, 潘旸, 等. 針對臨床實踐指南科學性, 透明性和適用性的評級工具研發. 中華醫學雜志, 2022, 102(30): 9.
15.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
16.	Sterne JAC, Savovi? J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
17.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
18.	Institute of Health Economics. Development of a quality appraisal tool for case series studies using a modified Delphi technique. 2012.
19.	Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health, 2022, 25(1): 3-9.
20.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
21.	Lewin S, Booth A, Glenton C, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implement Sci, 2018, 13(Suppl 1): 2.
22.	Guyatt GH, Alonso-Coello P, Schünemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol, 2016, 80: 3-7.
23.	Vernooij RW, Alonso-Coello P, Brouwers M, et al. Reporting items for updated clinical guidelines: checklist for the reporting of updated guidelines (CheckUp). PLoS Med, 2017, 14(1): e1002207.
24.	Miyashita H, Satoi S, Kuno T, et al. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat, 2020, 181(2): 279-289.
25.	Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol, 2017, 5(7): 513-523.
26.	Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 2012, 379(9810): 39-46.
27.	Hirooka Y, Nozaki Y, Okuda S, et al. Four-year teriparatide followed by denosumab vs. continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Front Endocrinol (Lausanne), 2021, 12: 753185.
28.	Adami G, Gavioli I, Rossini M, et al. Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskelet Dis, 2022, 14: 1759720X221105009.
29.	Jeong C, Ha J, Kim J, et al. The efficacy of denosumab in Korean male patients with osteoporosis. Korean J Intern Med, 2022, 37(5): 1011-1020.
30.	Morin SN, Leslie WD, Schousboe JT. Osteoporosis: a review. JAMA, 2025, 334(10): 894-907.
31.	信立泰(蘇州)藥業有限公司. 欣復泰(特立帕肽注射液)說明書. 2024.
32.	Lilly USA LLC. FORTEO (teriparatide injection), for subcutaneous use. 2024.
33.	Theramex Ireland Limited. Livogiva 20 micrograms/80 microliters solution for injection in pre-filled pen. 2020.
34.	Ouyang Y, Chen S, Wan T, et al. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2021, 100(7): e24839.
35.	Liu ZM, Zhang M, Zong Y, et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: a meta-analysis and systematic review of randomized controlled trials. PLoS One, 2022, 17(5): e0267706.
36.	Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med, 2004, 164(18): 2024-2030.
37.	Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res, 2013, 28(6): 1355-1368.
38.	Chen CH, Elsalmawy AH, Ish-Shalom S, et al. The effect of teriparatide treatment on the risk of fragility fractures in postmenopausal women with osteoporosis: results from the Asian and Latin America fracture observational study (ALAFOS). Calcif Tissue Int, 2022, 110(1): 74-86.
39.	Kong M, Zhou C, Zhu K, et al. 12-month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women. Clin Interv Aging, 2019, 14: 1693-1703.
40.	Amgen Manufacturing Limited Liability Company. Prolia? (denosumab injection), for subcutaneous use. 2024.
41.	李梅, 章振林, 夏維波. 骨質疏松癥藥物治療的必由之路: 長程序貫治療. 中華骨質疏松和骨礦鹽疾病雜志, 2021, 14(5): 441-446.
42.	Cano A, Silvan JM, Estévez A, et al. Spanish Menopause Society position statement: use of denosumab in postmenopausal women. Maturitas, 2014, 79(1): 117-121.
43.	中華醫學會骨科學分會創傷骨科學組, 中華醫學會骨科學分會外固定與肢體重建學組, 國家骨科與運動康復臨床醫學研究中心, 等. 中國脆性骨折術后規范化抗骨質疏松治療指南(2021). 中華創傷骨科雜志, 2021, 23(2): 93-101.
44.	中華醫學會, 中華醫學會臨床藥學分會, 中華醫學會雜志社, 等. 骨質疏松癥基層合理用藥指南. 中華全科醫師雜志, 2021, 20(5): 523-529.
45.	Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos, 2022, 17(1): 58.
46.	Sardar ZM, Coury JR, Cerpa M, et al. Best practice guidelines for assessment and management of osteoporosis in adult patients undergoing elective spinal reconstruction. Spine (Phila Pa 1976), 2022, 47(2): 128-135.
47.	Bhadada SK, Chadha M, Sriram U, et al. The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults. Arch Osteoporos, 2021, 16(1): 102.
48.	El Miedany Y, Paruk F, Kalla A, et al. Consensus evidence-based clinical practice guidelines for the diagnosis and treat-to-target management of osteoporosis in Africa: an initiative by the African Society of Bone Health and Metabolic Bone Diseases. Arch Osteoporos, 2021, 16(1): 176.
49.	Gómez O, Talero AP, Zanchetta MB, et al. Diagnostic, treatment, and follow-up of osteoporosis-position statement of the Latin American Federation of Endocrinology. Arch Osteoporos, 2021, 16(1): 114.
50.	Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract, 2020, 26(Suppl 1): 1-46.
51.	Fontalis A, Kenanidis E, Prousali E, et al. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. Expert Opin Drug Saf, 2018, 17(4): 413-428.
52.	Zhu Y, Huang Z, Wang Y, et al. The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: a review. J Orthop Translat, 2019, 22: 7-13.
53.	Yavropoulou MP, Kasdagli MI, Makras P, et al. Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials. Maturitas, 2024, 179: 107874.
54.	Watts NB, Aggers D, McCarthy EF, et al. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res, 2017, 32(5): 1027-1033.
55.	Hilbe W, Abacioglu U, Aebersold DM, et al. CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. Memo, 2013, 6(2): 75-82.
56.	Amgen Manufacturing Limited Liability Company. Jubbonti (denosumab) 60 mg solution for injection in pre-filled syringe. 2024.
57.	Laboratoire Fran?ais du Fractionnement et des Biotechnologies (LFB). FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen. 2022.
58.	Diker-Cohen T, Rosenberg D, Avni T, et al. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2020, 105(5): dgz322.
59.	于佳麗, 何娜, 邱婷婷, 等. 地舒單抗注射液治療骨質疏松癥的單中心回顧性分析. 中國合理用藥探索, 2022, 19(7): 1-6.
60.	Ishikawa K, Nagai T, Sakamoto K, et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag, 2016, 12: 1831-1840.
61.	Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer, 2015, 51(13): 1812-1821.
62.	Ikesue H, Tsuji T, Hata K, et al. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother, 2014, 48(9): 1159-1165.
63.	Park SY, Kim J, Chung HY. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report. Osteoporos Int, 2022, 33(1): 305-308.
64.	Camponovo C, Aubry-Rozier B, Lamy O, et al. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int, 2020, 31(12): 2485-2491.
65.	何悅, 陳珩, 安金剛, 等. 藥物相關性頜骨壞死臨床診療專家共識. 中國口腔頜面外科雜志, 2023, 21(4): 313-325.
66.	晁愛軍, 楊立, 馬賁, 等. 天津市抗骨質疏松治療與藥物相關性頜骨壞死問題的專家共識. 天津醫藥, 2023, 51(9): 897-903.
67.	Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, et al. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res, 2016, 27(3): 367-375.
68.	Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev, 2022, (7): CD012432.
69.	Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol, 2010, 28(35): 5132-5139.
70.	鄢榮, 黃琳, 游藍. 地舒單抗不良反應信號挖掘與分析. 中國醫院藥學雜志, 2022, 42(15): 1573-1577.
71.	Khan AA, Alrob HA, Ali DS, et al. Guideline No. 422g: menopause and osteoporosis. J Obstet Gynaecol Can, 2022, 44(5): 527-536.
72.	Brown JE, Handforth C, Compston JE, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol, 2020, 25: 100311.
73.	Kirazl? Y, Atamaz ?al?? F, El ?, et al. Updated approach for the management of osteoporosis in Turkey: a consensus report. Arch Osteoporos, 2020, 15(1): 137.
74.	李寧, 李新萍, 楊明輝, 等. 老年髖部骨折的骨質疏松癥診療專家共識. 中華骨與關節外科雜志, 2021, 14(8): 657-663.
75.	章振林, 夏維波, 李梅, 等. 男性骨質疏松癥診療指南. 中華內分泌代謝雜志, 2020, 36(10): 817-827.
76.	Edouard T, Guillaume-Czitrom S, Bacchetta J, et al. Guidelines for the management of children at risk of secondary bone fragility: expert opinion of a French working group. Arch Pediatr, 2020, 27(7): 393-398.
77.	García Martín A, Alhambra Expósito MR, Cortés Berdonces M, et al. Guide of management of alterations in mineral and bone metabolism during gestation and lactation. Endocrinol Diabetes Nutr (Engl Ed), 2022, 69(7): 530-539.
78.	Pereira RMR, Perez MO, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020). Arch Osteoporos, 2021, 16(1): 49.
79.	Gilsenan A, Midkiff K, Harris D, et al. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res, 2021, 36(2): 244-251.
80.	Gilsenan A, Midkiff K, Harris D, et al. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf, 2020, 29(12): 1616-1626.
81.	Benson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clin Pharmacol Ther, 2003, 73(1): 87-94.
82.	Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther, 2004, 26(6): 841-854.
83.	崔璨, 衛紅濤, 程晟, 等. 特立帕肽不良反應分析. 中國藥物警戒, 2022, 19(3): 333-335.
84.	Minisola S, Marin F, Kendler DL, et al. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Arch Osteoporos, 2019, 14(1): 10.
85.	Licata AA. Osteoporosis, teriparatide, and dosing of calcium and vitamin D. N Engl J Med, 2005, 352(18): 1930-1931.
86.	Thiruchelvam N, Randhawa J, Sadiek H, et al. Teriparatide induced delayed persistent hypercalcemia. Case Rep Endocrinol, 2014, 2014: 802473.
87.	齊魯制藥有限公司. 地舒單抗注射液說明書(魯可欣). 2023.
88.	Amgen Inc. XGEVA (denosumab) 120 mg solution for injection. 2020.
89.	Chen CH, Lo WC, Hu PJ, et al. Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis. Front Pharmacol, 2022, 13: 822178.
90.	Evenepoel P, Cunningham J, Ferrari S, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant, 2021, 36(1): 42-59.
91.	Broadwell A, Chines A, Ebeling PR, et al. Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab, 2021, 106(2): 397-409.
92.	Saeki C, Saito M, Oikawa T, et al. Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol, 2020, 26(33): 4960-4971.
93.	Laroche M, Talibart M, Cormier C, et al. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int, 2017, 28(11): 3135-3142.
94.	Polat SB, Evranos B, Aydin C, et al. Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature. Gynecol Endocrinol, 2015, 31(7): 522-525.
95.	Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP, et al. Case report: teriparatide treatment in a case of severe pregnancy -and lactation- associated osteoporosis. Hormones (Athens), 2012, 11(4): 495-500.
96.	Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab, 2008, 93(9): 3389-3395.
97.	Bernardor J, Flammier S, Cabet S, et al. Intermittent bi-daily sub-cutaneous teriparatide administration in children with hypoparathyroidism: a single-center experience. Front Pediatr, 2021, 9: 764040.
98.	姜紅峰, 彭紹蓉, 黃蔡華, 等. 特立帕肽治療老年性骨質疏松癥的療效及生活質量改善. 醫藥導報, 2017, 36(6): 622-625.
99.	陳柏齡, 呂中, 艾克熱木江·木合熱木, 等. 特立帕肽治療老年絕經后骨質疏松癥對患者生活質量的影響及安全性評估. 中國骨科臨床與基礎研究雜志, 2018, 10(5): 261-265.
100.	Munekawa C, Hashimoto Y, Kitagawa N, et al. Effect of teriparatide on bone mineral density and trabecular bone score in type 2 diabetic patients with osteoporosis: a retrospective cohort study. Medicina (Kaunas), 2022, 58(4): 481.
101.	Miyauchi A, Matsumoto T, Shigeta H, et al. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab, 2008, 26(6): 624-634.
102.	Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int, 2006, 17(3): 373-378.
103.	Hagino H, Sugimoto T, Tanaka S, et al. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention trial-05. Osteoporos Int, 2021, 32(11): 2301-2311.
104.	Chen JF, Yang KH, Zhang ZL, et al. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia. Osteoporos Int, 2015, 26(1): 11-28.
105.	Wang QY, Ding N, Dong YH, et al. Pharmacological treatment of osteoporosis in elderly people: a systematic review and meta-analysis. Gerontology, 2021, 67(6): 639-649.
106.	邊平達, 潘宏華. 特立帕肽致女性骨質疏松患者下肢肌肉痛性痙攣3例. 中國新藥與臨床雜志, 2015, 34(1): 77-78.
107.	蔡穎. 特立帕肽致過敏性休克1例. 藥學與臨床研究, 2015, 23(6): 601.
108.	Kim J, Konkel K, Jones SC, et al. Teriparatide-associated calciphylaxis: a case series. Osteoporos Int, 2022, 33(2): 499-504.
109.	Ziffra JB, Olshansky B. Teriparatide-induced atrial tachycardia. BMJ Case Rep, 2018, 2018: bcr2017223035.
110.	Echeverri AF, Ospina FE, Ca?as CA, et al. Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients. Br J Dermatol, 2016, 175(5): 1049-1051.
111.	Htet TD, Eisman JA, Elder GJ, et al. Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide. Osteoporos Int, 2018, 29(2): 517-518.
112.	Imai H, Watanabe M, Fujita T, et al. Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. Int J Clin Pharmacol Ther, 2014, 52(2): 166-174.
113.	Gielen E, Bergmann P, Bruyère O, et al. Osteoporosis in frail patients: a consensus paper of the Belgian Bone Club. Calcif Tissue Int, 2017, 101(2): 111-131.
114.	Brown JP, Fortier M, Frame H, et al. Canadian consensus conference on osteoporosis, 2006 update. J Obstet Gynaecol Can, 2006, 28(2 Suppl 1): S95-S112.
115.	Khanal A, Castelino RL, Peterson GM, et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources. Intern Med J, 2014, 44(1): 77-85.
116.	張許, 陳文文, 劉燕琳, 等. 特立帕肽和地舒單抗治療骨質疏松的Mini衛生技術評估. 今日藥學, 2022, 32(8): 611-617.
117.	Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int, 2007, 18(1): 59-68.
118.	McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 2006, 354(8): 821-831.
119.	Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344(19): 1434-1441.
120.	Ramchand SK, David NL, Leder BZ, et al. Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT. J Clin Endocrinol Metab, 2020, 105(3): 890-897.
121.	安進生物技術咨詢(上海)有限公司. 普羅力(地舒單抗注射液)說明書. 2024.
122.	中華醫學會骨質疏松和骨礦鹽疾病分會, 謝忠建, 章振林, 等. 維生素D及其類似物的臨床應用共識(2025版). 中華骨質疏松和骨礦鹽疾病雜志, 2025, 18(5): 497-517.
123.	Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab, 2020, 105(3): dgaa048.
124.	Gregson CL, Armstrong DJ, Avgerinou C, et al. National Osteoporosis Guideline Group (NOGG). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos, 2025, 20(1): 119.
125.	Nakamura Y, Suzuki T, Kamimura M, et al. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res, 2017, 5: 17021.
126.	Suzuki T, Nakamura Y, Kato H. Vitamin D and calcium addition during denosumab therapy over a period of four years significantly improves lumbar bone mineral density in Japanese osteoporosis patients. Nutrients, 2018, 10(3): 272.
127.	Suzuki T, Nakamura Y, Kato H. Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. Ther Clin Risk Manag, 2018, 15: 15-22.
128.	Lilly USA LLC. FORTEO (teriparatide injection), for subcutaneous use. 2021.
129.	Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med, 2007, 357(20): 2028-2039.
130.	Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 2018, 391(10117): 230-240.
131.	邱敏麗, 謝雅, 王曉紅, 等. 骨質疏松癥患者實踐指南. 中華內科雜志, 2020, 59(12): 953-959.
132.	Suzuki T, Nakamura Y, Tanaka M, et al. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Mod Rheumatol, 2018, 28(2): 376-379.
133.	Saito S, Sugo Y, Tsuburai T, et al. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. J Obstet Gynaecol Res, 2019, 45(4): 908-914.
134.	Ebina K, Kashii M, Hirao M, et al. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. J Bone Miner Metab, 2017, 35(5): 571-580.
135.	Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 2009, 361(8): 756-765.
136.	Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab, 2014, 99(7): 2599-2607.
137.	中國健康促進基金會基層醫療機構骨質疏松癥診斷與治療專家共識委員會. 基層醫療機構骨質疏松癥診斷和治療專家共識(2021). 中國骨質疏松雜志, 2021, 27(7): 937-944.
138.	翟曉, 楊新明, 劉芳宏, 等. 特立帕肽聯合利塞膦酸鈉治療骨質疏松椎體壓縮骨折患者的骨代謝. 中國組織工程研究, 2022, 26(35): 5685-5692.
139.	Sun Y, Li Y, Li J, et al. Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis. Front Pharmacol, 2022, 13: 888208.
140.	Zhang C, Song C. Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives. Front Pharmacol, 2021, 11: 607017.
141.	高倩, 陳云霞, 代嘉, 等. 特立帕肽聯合雷洛昔芬對絕經后骨質疏松癥患者骨代謝異常的改善效果. 疑難病雜志, 2020, 19(3): 257-260, 265.
142.	Sobh MM, Abdalbary M, Elnagar S, et al. Secondary osteoporosis and metabolic bone diseases. J Clin Med, 2022, 11(9): 2382.
143.	李梅, 夏維波, 章振林. 骨轉換生化標志物臨床應用指南. 中華骨質疏松和骨礦鹽疾病雜志, 2021, 14(4): 321-336.
144.	Watts NB, Brown JP, Papapoulos S, et al. Safety observations with 3 years of denosumab exposure: comparison between subjects who received denosumab during the randomized freedom trial and subjects who crossed over to denosumab during the FREEDOM extension. J Bone Miner Res, 2017, 32(7): 1481-1485.
145.	Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 2020, 21(1): 60-72.
146.	Inada A, Hosohata K, Oyama S, et al. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Ther Clin Risk Manag, 2018, 15: 59-64.
147.	Seki K, Kaneko T, Kamimoto A, et al. Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: a retrospective cohort study. J Dent Sci, 2022, 17(4): 1619-1625.
148.	陳遠程, 吳文, 許翎, 等. 地舒單抗治療的原發性骨質疏松癥患者血鈣及骨代謝標志物的動態變化. 南方醫科大學學報, 2025, 45(4): 760-764.
149.	Ifuku E, Yoshimura T, Uzawa T, et al. Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk. Osteoporos Sarcopenia, 2019, 5(2): 44-50.
150.	楊乃龍, 劉煥娜, 馬學曉, 等. 青島地區特立帕肽治療絕經后重度骨質疏松癥6個月(階段性)有效性和安全性. 中華骨質疏松和骨礦鹽疾病雜志, 2018, 11(5): 469-474.
151.	趙俊, 徐文, 倪倍倍, 等. 特立帕肽致不良反應文獻分析. 中國醫院藥學雜志, 2021, 41(12): 1249-1254.
152.	Radominski SC, Bernardo W, Paula AP, et al. Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Rev Bras Reumatol Engl Ed, 2017: 57(Suppl 2): 452-466.
153.	Miller PD, Bilezikian JP, Diaz-Curiel M, et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab, 2007, 92(9): 3535-3541.
154.	Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int, 2017, 28(3): 775-780.
155.	Secretaría de Salud, México. Guía de Consulta para el médico de 1er nivel de atención. Prevención, diagnóstico y tratamiento de la osteoporosis. 2017.
156.	Minisola S, Piemonte S, Del Fiacco R, et al. Measuring serum calcium before and after teriparatide treatment. Osteoporos Int, 2008, 19(12): 1807.
157.	Piemonte S, Romagnoli E, Cipriani C, et al. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1, 25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study. Calcif Tissue Int, 2009, 85(4): 287-292.
158.	Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int, 2020, 31(11): 2093-2102.
159.	Chen Q, Guo M, Ma X, et al. Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis. Horm Metab Res, 2019, 51(12): 785-791.
160.	Jensen AL, Lomborg K, Wind G, et al. Effectiveness and characteristics of multifaceted osteoporosis group education-a systematic review. Osteoporos Int, 2014, 25(4): 1209-1224.
161.	Lai P, Chua SS, Chan SP. A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis. Osteoporos Int, 2010, 21(10): 1637-1656.
162.	Smith CA. A systematic review of healthcare professional-led education for patients with osteoporosis or those at high risk for the disease. Orthop Nurs, 2010, 29(2): 119-132.
163.	White HJ, Bettiol SS, Perera R, et al. A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture. Fam Pract, 2010, 27(6): 593-603.
164.	Huang CF, Ho CJ, Lin SY, et al. Asia-Pacific consensus for the management of osteoporosis in men. Osteoporos Int, 2025, 36(7): 1105-1114.
165.	Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int, 2009, 20(4): 625-630.
166.	中華人民共和國國家衛生健康委員會. 醫療機構用藥教育服務規范. 2021.
167.	Scottish Intercollegiate Guidelines Network. Management of osteoporosis and the prevention of fragility fractures. 2021.
168.	ACOG Committee on Clinical Practice Guidelines–Gynecology. Management of postmenopausal osteoporosis: ACOG clinical practice guideline No. 2. Obstet Gynecol, 2022, 139(4): 698-717.
169.	Hoong CWS, Saul D, Khosla S, et al. Advances in the management of osteoporosis. BMJ, 2025, 390: e081250.
170.	Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab, 2021, 106(1): 264-281.
171.	S?lling AS, Harsl?f T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res, 2021, 36(7): 1245-1254.
172.	Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 2005, 353(6): 555-565.
173.	Burkard D, Beckett T, Kourtjian E, et al. Effects of bone remodeling agents following teriparatide treatment. Osteoporos Int, 2018, 29(6): 1351-1357.
174.	Adami S, San Martin J, Mu?oz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int, 2008, 19(1): 87-94.
175.	Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res, 2009, 24(4): 726-736.
176.	Lee S, Hong N, Kim KJ, et al. Bone density after teriparatide discontinuation with or without antiresorptive therapy in pregnancy- and lactation-associated osteoporosis. Calcif Tissue Int, 2021, 109(5): 544-553.
177.	中華醫學會. 原發性骨質疏松癥基層診療指南(2019年). 中華全科醫師雜志, 2020, 19(4): 304-315.

1. 鈣劑預防成人原發性骨質疏松癥臨床實踐指南工作組. 鈣劑預防成人原發性骨質疏松癥的臨床實踐指南. 中國循證醫學雜志, 2024, 24(10): 1117-1128.
2. 中國疾病預防控制中心慢性非傳染性疾病預防控制中心, 中華醫學會骨質疏松和骨礦鹽疾病分會. 中國骨質疏松癥流行病學調查報告(2018). 北京: 人民衛生出版社, 2021.
3. 中華醫學會骨質疏松和骨礦鹽疾病分會. 原發性骨質疏松癥診療指南(2022). 中國全科醫學, 2023, 26(14): 1671-1691.
4. 中國醫師協會風濕免疫科醫師分會, 中華醫學會風濕病學分會, 中華醫學會骨質疏松和骨礦鹽疾病分會, 等. 2020版中國糖皮質激素性骨質疏松癥防治專家共識. 中華內科雜志, 2021, 60(1): 13-21.
5. 中國老年學和老年醫學學會骨質疏松分會婦產科專家委員會與圍絕經期骨質疏松防控培訓部. 圍絕經期和絕經后婦女骨質疏松防治專家共識. 中國臨床醫生雜志, 2020, 48(8): 903-908.
6. 《中國老年骨質疏松癥診療指南2023》工作組, 中國老年學和老年醫學學會骨質疏松分會, 中國醫療保健國際交流促進會骨質疏松病學分會, 等. 中國老年骨質疏松癥診療指南(2023). 中華骨與關節外科雜志, 2023, 16(10): 865-885.
7. 中華醫學會骨質疏松和骨礦鹽疾病分會. 男性骨質疏松癥診療指南. 中華骨質疏松和骨礦鹽疾病雜志, 2020, 13(5): 381-395.
8. 中華醫學會骨質疏松和骨礦鹽疾病分會. 地舒單抗在骨質疏松癥臨床合理用藥的中國專家建議. 中華骨質疏松和骨礦鹽疾病雜志, 2020, 13(6): 499-508.
9. 中國康復技術轉化與發展促進會骨質疏松性骨折加速康復專業委員會, 中華醫學會骨質疏松和骨礦鹽疾病委員會骨與關節學組, 中國醫師協會骨科醫師分會骨質疏松工作委員會. 特立帕肽治療骨質疏松性骨折中國專家共識(2024版). 中華醫學雜志, 2024, 104(17): 1456-1465.
10. World Health Organization. WHO handbook for guideline development (2nd edition). 2014.
11. Schünemann F, Meerpohl JJ, Schwingshackl L, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Z Evid Fortbild Qual Gesundhwes, 2021, 163: 76-84.
12. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol, 2010, 63(12): 1308-1311.
13. Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
14. 楊楠, 趙巍, 潘旸, 等. 針對臨床實踐指南科學性, 透明性和適用性的評級工具研發. 中華醫學雜志, 2022, 102(30): 9.
15. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
16. Sterne JAC, Savovi? J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
18. Institute of Health Economics. Development of a quality appraisal tool for case series studies using a modified Delphi technique. 2012.
19. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health, 2022, 25(1): 3-9.
20. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
21. Lewin S, Booth A, Glenton C, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implement Sci, 2018, 13(Suppl 1): 2.
22. Guyatt GH, Alonso-Coello P, Schünemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol, 2016, 80: 3-7.
23. Vernooij RW, Alonso-Coello P, Brouwers M, et al. Reporting items for updated clinical guidelines: checklist for the reporting of updated guidelines (CheckUp). PLoS Med, 2017, 14(1): e1002207.
24. Miyashita H, Satoi S, Kuno T, et al. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat, 2020, 181(2): 279-289.
25. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol, 2017, 5(7): 513-523.
26. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 2012, 379(9810): 39-46.
27. Hirooka Y, Nozaki Y, Okuda S, et al. Four-year teriparatide followed by denosumab vs. continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Front Endocrinol (Lausanne), 2021, 12: 753185.
28. Adami G, Gavioli I, Rossini M, et al. Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskelet Dis, 2022, 14: 1759720X221105009.
29. Jeong C, Ha J, Kim J, et al. The efficacy of denosumab in Korean male patients with osteoporosis. Korean J Intern Med, 2022, 37(5): 1011-1020.
30. Morin SN, Leslie WD, Schousboe JT. Osteoporosis: a review. JAMA, 2025, 334(10): 894-907.
31. 信立泰(蘇州)藥業有限公司. 欣復泰(特立帕肽注射液)說明書. 2024.
32. Lilly USA LLC. FORTEO (teriparatide injection), for subcutaneous use. 2024.
33. Theramex Ireland Limited. Livogiva 20 micrograms/80 microliters solution for injection in pre-filled pen. 2020.
34. Ouyang Y, Chen S, Wan T, et al. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2021, 100(7): e24839.
35. Liu ZM, Zhang M, Zong Y, et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: a meta-analysis and systematic review of randomized controlled trials. PLoS One, 2022, 17(5): e0267706.
36. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med, 2004, 164(18): 2024-2030.
37. Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res, 2013, 28(6): 1355-1368.
38. Chen CH, Elsalmawy AH, Ish-Shalom S, et al. The effect of teriparatide treatment on the risk of fragility fractures in postmenopausal women with osteoporosis: results from the Asian and Latin America fracture observational study (ALAFOS). Calcif Tissue Int, 2022, 110(1): 74-86.
39. Kong M, Zhou C, Zhu K, et al. 12-month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women. Clin Interv Aging, 2019, 14: 1693-1703.
40. Amgen Manufacturing Limited Liability Company. Prolia? (denosumab injection), for subcutaneous use. 2024.
41. 李梅, 章振林, 夏維波. 骨質疏松癥藥物治療的必由之路: 長程序貫治療. 中華骨質疏松和骨礦鹽疾病雜志, 2021, 14(5): 441-446.
42. Cano A, Silvan JM, Estévez A, et al. Spanish Menopause Society position statement: use of denosumab in postmenopausal women. Maturitas, 2014, 79(1): 117-121.
43. 中華醫學會骨科學分會創傷骨科學組, 中華醫學會骨科學分會外固定與肢體重建學組, 國家骨科與運動康復臨床醫學研究中心, 等. 中國脆性骨折術后規范化抗骨質疏松治療指南(2021). 中華創傷骨科雜志, 2021, 23(2): 93-101.
44. 中華醫學會, 中華醫學會臨床藥學分會, 中華醫學會雜志社, 等. 骨質疏松癥基層合理用藥指南. 中華全科醫師雜志, 2021, 20(5): 523-529.
45. Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos, 2022, 17(1): 58.
46. Sardar ZM, Coury JR, Cerpa M, et al. Best practice guidelines for assessment and management of osteoporosis in adult patients undergoing elective spinal reconstruction. Spine (Phila Pa 1976), 2022, 47(2): 128-135.
47. Bhadada SK, Chadha M, Sriram U, et al. The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults. Arch Osteoporos, 2021, 16(1): 102.
48. El Miedany Y, Paruk F, Kalla A, et al. Consensus evidence-based clinical practice guidelines for the diagnosis and treat-to-target management of osteoporosis in Africa: an initiative by the African Society of Bone Health and Metabolic Bone Diseases. Arch Osteoporos, 2021, 16(1): 176.
49. Gómez O, Talero AP, Zanchetta MB, et al. Diagnostic, treatment, and follow-up of osteoporosis-position statement of the Latin American Federation of Endocrinology. Arch Osteoporos, 2021, 16(1): 114.
50. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract, 2020, 26(Suppl 1): 1-46.
51. Fontalis A, Kenanidis E, Prousali E, et al. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. Expert Opin Drug Saf, 2018, 17(4): 413-428.
52. Zhu Y, Huang Z, Wang Y, et al. The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: a review. J Orthop Translat, 2019, 22: 7-13.
53. Yavropoulou MP, Kasdagli MI, Makras P, et al. Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials. Maturitas, 2024, 179: 107874.
54. Watts NB, Aggers D, McCarthy EF, et al. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res, 2017, 32(5): 1027-1033.
55. Hilbe W, Abacioglu U, Aebersold DM, et al. CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. Memo, 2013, 6(2): 75-82.
56. Amgen Manufacturing Limited Liability Company. Jubbonti (denosumab) 60 mg solution for injection in pre-filled syringe. 2024.
57. Laboratoire Fran?ais du Fractionnement et des Biotechnologies (LFB). FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen. 2022.
58. Diker-Cohen T, Rosenberg D, Avni T, et al. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2020, 105(5): dgz322.
59. 于佳麗, 何娜, 邱婷婷, 等. 地舒單抗注射液治療骨質疏松癥的單中心回顧性分析. 中國合理用藥探索, 2022, 19(7): 1-6.
60. Ishikawa K, Nagai T, Sakamoto K, et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag, 2016, 12: 1831-1840.
61. Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer, 2015, 51(13): 1812-1821.
62. Ikesue H, Tsuji T, Hata K, et al. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother, 2014, 48(9): 1159-1165.
63. Park SY, Kim J, Chung HY. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report. Osteoporos Int, 2022, 33(1): 305-308.
64. Camponovo C, Aubry-Rozier B, Lamy O, et al. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int, 2020, 31(12): 2485-2491.
65. 何悅, 陳珩, 安金剛, 等. 藥物相關性頜骨壞死臨床診療專家共識. 中國口腔頜面外科雜志, 2023, 21(4): 313-325.
66. 晁愛軍, 楊立, 馬賁, 等. 天津市抗骨質疏松治療與藥物相關性頜骨壞死問題的專家共識. 天津醫藥, 2023, 51(9): 897-903.
67. Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, et al. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res, 2016, 27(3): 367-375.
68. Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev, 2022, (7): CD012432.
69. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol, 2010, 28(35): 5132-5139.
70. 鄢榮, 黃琳, 游藍. 地舒單抗不良反應信號挖掘與分析. 中國醫院藥學雜志, 2022, 42(15): 1573-1577.
71. Khan AA, Alrob HA, Ali DS, et al. Guideline No. 422g: menopause and osteoporosis. J Obstet Gynaecol Can, 2022, 44(5): 527-536.
72. Brown JE, Handforth C, Compston JE, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol, 2020, 25: 100311.
73. Kirazl? Y, Atamaz ?al?? F, El ?, et al. Updated approach for the management of osteoporosis in Turkey: a consensus report. Arch Osteoporos, 2020, 15(1): 137.
74. 李寧, 李新萍, 楊明輝, 等. 老年髖部骨折的骨質疏松癥診療專家共識. 中華骨與關節外科雜志, 2021, 14(8): 657-663.
75. 章振林, 夏維波, 李梅, 等. 男性骨質疏松癥診療指南. 中華內分泌代謝雜志, 2020, 36(10): 817-827.
76. Edouard T, Guillaume-Czitrom S, Bacchetta J, et al. Guidelines for the management of children at risk of secondary bone fragility: expert opinion of a French working group. Arch Pediatr, 2020, 27(7): 393-398.
77. García Martín A, Alhambra Expósito MR, Cortés Berdonces M, et al. Guide of management of alterations in mineral and bone metabolism during gestation and lactation. Endocrinol Diabetes Nutr (Engl Ed), 2022, 69(7): 530-539.
78. Pereira RMR, Perez MO, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020). Arch Osteoporos, 2021, 16(1): 49.
79. Gilsenan A, Midkiff K, Harris D, et al. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res, 2021, 36(2): 244-251.
80. Gilsenan A, Midkiff K, Harris D, et al. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf, 2020, 29(12): 1616-1626.
81. Benson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clin Pharmacol Ther, 2003, 73(1): 87-94.
82. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther, 2004, 26(6): 841-854.
83. 崔璨, 衛紅濤, 程晟, 等. 特立帕肽不良反應分析. 中國藥物警戒, 2022, 19(3): 333-335.
84. Minisola S, Marin F, Kendler DL, et al. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Arch Osteoporos, 2019, 14(1): 10.
85. Licata AA. Osteoporosis, teriparatide, and dosing of calcium and vitamin D. N Engl J Med, 2005, 352(18): 1930-1931.
86. Thiruchelvam N, Randhawa J, Sadiek H, et al. Teriparatide induced delayed persistent hypercalcemia. Case Rep Endocrinol, 2014, 2014: 802473.
87. 齊魯制藥有限公司. 地舒單抗注射液說明書(魯可欣). 2023.
88. Amgen Inc. XGEVA (denosumab) 120 mg solution for injection. 2020.
89. Chen CH, Lo WC, Hu PJ, et al. Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis. Front Pharmacol, 2022, 13: 822178.
90. Evenepoel P, Cunningham J, Ferrari S, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant, 2021, 36(1): 42-59.
91. Broadwell A, Chines A, Ebeling PR, et al. Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab, 2021, 106(2): 397-409.
92. Saeki C, Saito M, Oikawa T, et al. Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol, 2020, 26(33): 4960-4971.
93. Laroche M, Talibart M, Cormier C, et al. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int, 2017, 28(11): 3135-3142.
94. Polat SB, Evranos B, Aydin C, et al. Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature. Gynecol Endocrinol, 2015, 31(7): 522-525.
95. Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP, et al. Case report: teriparatide treatment in a case of severe pregnancy -and lactation- associated osteoporosis. Hormones (Athens), 2012, 11(4): 495-500.
96. Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab, 2008, 93(9): 3389-3395.
97. Bernardor J, Flammier S, Cabet S, et al. Intermittent bi-daily sub-cutaneous teriparatide administration in children with hypoparathyroidism: a single-center experience. Front Pediatr, 2021, 9: 764040.
98. 姜紅峰, 彭紹蓉, 黃蔡華, 等. 特立帕肽治療老年性骨質疏松癥的療效及生活質量改善. 醫藥導報, 2017, 36(6): 622-625.
99. 陳柏齡, 呂中, 艾克熱木江·木合熱木, 等. 特立帕肽治療老年絕經后骨質疏松癥對患者生活質量的影響及安全性評估. 中國骨科臨床與基礎研究雜志, 2018, 10(5): 261-265.
100. Munekawa C, Hashimoto Y, Kitagawa N, et al. Effect of teriparatide on bone mineral density and trabecular bone score in type 2 diabetic patients with osteoporosis: a retrospective cohort study. Medicina (Kaunas), 2022, 58(4): 481.
101. Miyauchi A, Matsumoto T, Shigeta H, et al. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab, 2008, 26(6): 624-634.
102. Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int, 2006, 17(3): 373-378.
103. Hagino H, Sugimoto T, Tanaka S, et al. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention trial-05. Osteoporos Int, 2021, 32(11): 2301-2311.
104. Chen JF, Yang KH, Zhang ZL, et al. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia. Osteoporos Int, 2015, 26(1): 11-28.
105. Wang QY, Ding N, Dong YH, et al. Pharmacological treatment of osteoporosis in elderly people: a systematic review and meta-analysis. Gerontology, 2021, 67(6): 639-649.
106. 邊平達, 潘宏華. 特立帕肽致女性骨質疏松患者下肢肌肉痛性痙攣3例. 中國新藥與臨床雜志, 2015, 34(1): 77-78.
107. 蔡穎. 特立帕肽致過敏性休克1例. 藥學與臨床研究, 2015, 23(6): 601.
108. Kim J, Konkel K, Jones SC, et al. Teriparatide-associated calciphylaxis: a case series. Osteoporos Int, 2022, 33(2): 499-504.
109. Ziffra JB, Olshansky B. Teriparatide-induced atrial tachycardia. BMJ Case Rep, 2018, 2018: bcr2017223035.
110. Echeverri AF, Ospina FE, Ca?as CA, et al. Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients. Br J Dermatol, 2016, 175(5): 1049-1051.
111. Htet TD, Eisman JA, Elder GJ, et al. Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide. Osteoporos Int, 2018, 29(2): 517-518.
112. Imai H, Watanabe M, Fujita T, et al. Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. Int J Clin Pharmacol Ther, 2014, 52(2): 166-174.
113. Gielen E, Bergmann P, Bruyère O, et al. Osteoporosis in frail patients: a consensus paper of the Belgian Bone Club. Calcif Tissue Int, 2017, 101(2): 111-131.
114. Brown JP, Fortier M, Frame H, et al. Canadian consensus conference on osteoporosis, 2006 update. J Obstet Gynaecol Can, 2006, 28(2 Suppl 1): S95-S112.
115. Khanal A, Castelino RL, Peterson GM, et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources. Intern Med J, 2014, 44(1): 77-85.
116. 張許, 陳文文, 劉燕琳, 等. 特立帕肽和地舒單抗治療骨質疏松的Mini衛生技術評估. 今日藥學, 2022, 32(8): 611-617.
117. Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int, 2007, 18(1): 59-68.
118. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 2006, 354(8): 821-831.
119. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344(19): 1434-1441.
120. Ramchand SK, David NL, Leder BZ, et al. Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT. J Clin Endocrinol Metab, 2020, 105(3): 890-897.
121. 安進生物技術咨詢(上海)有限公司. 普羅力(地舒單抗注射液)說明書. 2024.
122. 中華醫學會骨質疏松和骨礦鹽疾病分會, 謝忠建, 章振林, 等. 維生素D及其類似物的臨床應用共識(2025版). 中華骨質疏松和骨礦鹽疾病雜志, 2025, 18(5): 497-517.
123. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab, 2020, 105(3): dgaa048.
124. Gregson CL, Armstrong DJ, Avgerinou C, et al. National Osteoporosis Guideline Group (NOGG). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos, 2025, 20(1): 119.
125. Nakamura Y, Suzuki T, Kamimura M, et al. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res, 2017, 5: 17021.
126. Suzuki T, Nakamura Y, Kato H. Vitamin D and calcium addition during denosumab therapy over a period of four years significantly improves lumbar bone mineral density in Japanese osteoporosis patients. Nutrients, 2018, 10(3): 272.
127. Suzuki T, Nakamura Y, Kato H. Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. Ther Clin Risk Manag, 2018, 15: 15-22.
128. Lilly USA LLC. FORTEO (teriparatide injection), for subcutaneous use. 2021.
129. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med, 2007, 357(20): 2028-2039.
130. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 2018, 391(10117): 230-240.
131. 邱敏麗, 謝雅, 王曉紅, 等. 骨質疏松癥患者實踐指南. 中華內科雜志, 2020, 59(12): 953-959.
132. Suzuki T, Nakamura Y, Tanaka M, et al. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Mod Rheumatol, 2018, 28(2): 376-379.
133. Saito S, Sugo Y, Tsuburai T, et al. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. J Obstet Gynaecol Res, 2019, 45(4): 908-914.
134. Ebina K, Kashii M, Hirao M, et al. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. J Bone Miner Metab, 2017, 35(5): 571-580.
135. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 2009, 361(8): 756-765.
136. Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab, 2014, 99(7): 2599-2607.
137. 中國健康促進基金會基層醫療機構骨質疏松癥診斷與治療專家共識委員會. 基層醫療機構骨質疏松癥診斷和治療專家共識(2021). 中國骨質疏松雜志, 2021, 27(7): 937-944.
138. 翟曉, 楊新明, 劉芳宏, 等. 特立帕肽聯合利塞膦酸鈉治療骨質疏松椎體壓縮骨折患者的骨代謝. 中國組織工程研究, 2022, 26(35): 5685-5692.
139. Sun Y, Li Y, Li J, et al. Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis. Front Pharmacol, 2022, 13: 888208.
140. Zhang C, Song C. Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives. Front Pharmacol, 2021, 11: 607017.
141. 高倩, 陳云霞, 代嘉, 等. 特立帕肽聯合雷洛昔芬對絕經后骨質疏松癥患者骨代謝異常的改善效果. 疑難病雜志, 2020, 19(3): 257-260, 265.
142. Sobh MM, Abdalbary M, Elnagar S, et al. Secondary osteoporosis and metabolic bone diseases. J Clin Med, 2022, 11(9): 2382.
143. 李梅, 夏維波, 章振林. 骨轉換生化標志物臨床應用指南. 中華骨質疏松和骨礦鹽疾病雜志, 2021, 14(4): 321-336.
144. Watts NB, Brown JP, Papapoulos S, et al. Safety observations with 3 years of denosumab exposure: comparison between subjects who received denosumab during the randomized freedom trial and subjects who crossed over to denosumab during the FREEDOM extension. J Bone Miner Res, 2017, 32(7): 1481-1485.
145. Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 2020, 21(1): 60-72.
146. Inada A, Hosohata K, Oyama S, et al. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Ther Clin Risk Manag, 2018, 15: 59-64.
147. Seki K, Kaneko T, Kamimoto A, et al. Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: a retrospective cohort study. J Dent Sci, 2022, 17(4): 1619-1625.
148. 陳遠程, 吳文, 許翎, 等. 地舒單抗治療的原發性骨質疏松癥患者血鈣及骨代謝標志物的動態變化. 南方醫科大學學報, 2025, 45(4): 760-764.
149. Ifuku E, Yoshimura T, Uzawa T, et al. Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk. Osteoporos Sarcopenia, 2019, 5(2): 44-50.
150. 楊乃龍, 劉煥娜, 馬學曉, 等. 青島地區特立帕肽治療絕經后重度骨質疏松癥6個月(階段性)有效性和安全性. 中華骨質疏松和骨礦鹽疾病雜志, 2018, 11(5): 469-474.
151. 趙俊, 徐文, 倪倍倍, 等. 特立帕肽致不良反應文獻分析. 中國醫院藥學雜志, 2021, 41(12): 1249-1254.
152. Radominski SC, Bernardo W, Paula AP, et al. Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Rev Bras Reumatol Engl Ed, 2017: 57(Suppl 2): 452-466.
153. Miller PD, Bilezikian JP, Diaz-Curiel M, et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab, 2007, 92(9): 3535-3541.
154. Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int, 2017, 28(3): 775-780.
155. Secretaría de Salud, México. Guía de Consulta para el médico de 1er nivel de atención. Prevención, diagnóstico y tratamiento de la osteoporosis. 2017.
156. Minisola S, Piemonte S, Del Fiacco R, et al. Measuring serum calcium before and after teriparatide treatment. Osteoporos Int, 2008, 19(12): 1807.
157. Piemonte S, Romagnoli E, Cipriani C, et al. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1, 25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study. Calcif Tissue Int, 2009, 85(4): 287-292.
158. Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int, 2020, 31(11): 2093-2102.
159. Chen Q, Guo M, Ma X, et al. Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis. Horm Metab Res, 2019, 51(12): 785-791.
160. Jensen AL, Lomborg K, Wind G, et al. Effectiveness and characteristics of multifaceted osteoporosis group education-a systematic review. Osteoporos Int, 2014, 25(4): 1209-1224.
161. Lai P, Chua SS, Chan SP. A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis. Osteoporos Int, 2010, 21(10): 1637-1656.
162. Smith CA. A systematic review of healthcare professional-led education for patients with osteoporosis or those at high risk for the disease. Orthop Nurs, 2010, 29(2): 119-132.
163. White HJ, Bettiol SS, Perera R, et al. A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture. Fam Pract, 2010, 27(6): 593-603.
164. Huang CF, Ho CJ, Lin SY, et al. Asia-Pacific consensus for the management of osteoporosis in men. Osteoporos Int, 2025, 36(7): 1105-1114.
165. Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int, 2009, 20(4): 625-630.
166. 中華人民共和國國家衛生健康委員會. 醫療機構用藥教育服務規范. 2021.
167. Scottish Intercollegiate Guidelines Network. Management of osteoporosis and the prevention of fragility fractures. 2021.
168. ACOG Committee on Clinical Practice Guidelines–Gynecology. Management of postmenopausal osteoporosis: ACOG clinical practice guideline No. 2. Obstet Gynecol, 2022, 139(4): 698-717.
169. Hoong CWS, Saul D, Khosla S, et al. Advances in the management of osteoporosis. BMJ, 2025, 390: e081250.
170. Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab, 2021, 106(1): 264-281.
171. S?lling AS, Harsl?f T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res, 2021, 36(7): 1245-1254.
172. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 2005, 353(6): 555-565.
173. Burkard D, Beckett T, Kourtjian E, et al. Effects of bone remodeling agents following teriparatide treatment. Osteoporos Int, 2018, 29(6): 1351-1357.
174. Adami S, San Martin J, Mu?oz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int, 2008, 19(1): 87-94.
175. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res, 2009, 24(4): 726-736.
176. Lee S, Hong N, Kim KJ, et al. Bone density after teriparatide discontinuation with or without antiresorptive therapy in pregnancy- and lactation-associated osteoporosis. Calcif Tissue Int, 2021, 109(5): 544-553.
177. 中華醫學會. 原發性骨質疏松癥基層診療指南(2019年). 中華全科醫師雜志, 2020, 19(4): 304-315.

Next Article
Clinical application guideline of combination with traditional Chinese medicine and Western medicine in the prevention and treatment of acute pharyngitis (2025)

Chinese Journal of Evidence-Based Medicine

Medication therapy of biological agents in osteoporosis: an evidence-based practice guideline (2025)

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content